The prenylflavonoids 6-prenylnaringenin (6-PN) and 8-prenylnaringenin (8-PN) are secondary plant substances, almost exclusively found in hops (Humulus lupulus). Both compounds have known potential biological properties, but poor bioavailability due to their low oral absorption and retention. Our study followed a single dose (500 mg 6- or 8-PN), placebo controlled, randomized, double-blind, three armed crossover study design with ≥2-week washout periods. Plasma, PBMC and urine samples were collected at intervals up to 24 h after intake. Investigators investigated the safety, pharmacokinetics and impact of oral prenylflavonoids on the function of cells of the immune system.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Mean area under the curve (AUC) of plasma concentration vs. time of total 6-prenylnaringenin [nmol/L*h]
Timeframe: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Mean area under the curve (AUC) of plasma concentration vs. time of total 8-prenylnaringenin [nmol/L*h]
Timeframe: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Mean maximum plasma concentration (Cmax) of total 6-prenylnaringenin [nmol/L]
Timeframe: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Mean maximum plasma concentration (Cmax) of total 8-prenylnaringenin [nmol/L]
Timeframe: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Time to reach maximum plasma concentration (Tmax) of total 6-prenylnaringenin [h]
Timeframe: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Time to reach maximum plasma concentration (Tmax) of total 8-prenylnaringenin [h]
Timeframe: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Cumulative urinary excretion of total 6-prenylnaringenin [nmol/g creatinine]
Timeframe: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Cumulative urinary excretion of total 8-prenylnaringenin [nmol/g creatinine]
Timeframe: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Cell count (dead cells/ml and living cells/ml) of PBMCs after 6-PN administration
Timeframe: 0, 6, and 24 h post dose
Cell count (dead cells/ml and living cells/ml) of PBMCs after 8-PN administration
Timeframe: 0, 6, and 24 h post dose
Cell viability of PBMCs after 6-PN administration
Timeframe: 0, 6, and 24 h post dose
Cell viability of PBMCs after 8-PN administration
Timeframe: 0, 6, and 24 h post dose